cad106
Vaccineexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00411580)
Timeline
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinImmunity, active
APP immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cad106
- cad106
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02565511 | Phase 2/Phase 3 (Phase 3) | Dec 2, 2015 | Alzheimer's Association, Amgen, National Institute on Aging (NIA), Novartis, University of Arizona |
| NCT01097096 | Phase 2 | Mar 1, 2010 | Novartis |
| NCT01023685 | Phase 2 | Dec 1, 2009 | Novartis |
| NCT00956410 | Phase 2 | Sep 1, 2009 | Novartis |
| NCT00795418 | Phase 2 | Oct 1, 2008 | Novartis |
| NCT00733863 | Phase 2 | Jul 1, 2008 | Novartis |
| NCT00411580 | Phase 1 | Jun 1, 2005 | Novartis |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 7 | 7 | 3 | 2005 |
| Alzheimer's Association | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Amgen | For profit | 1 | 0 | 1 | 2015 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2015 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1